Evidence map›Paper›PMID 38562821›Full record

ArticleResearch square2024

Nonpathogenic

Shaobo Yang, Michal Sheffer, Isabel E Kaplan, Zongqi Wang, Mubin Tarannum, Khanhlinh Dinh, Yasmin Abdulhamid, Roman Shapiro, Rebecca Porter, Robert Soiffer and 17 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Shaobo YangDepartment of Bioengineering, Northeastern University, Boston, MA.
Michal ShefferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Isabel E KaplanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Zongqi WangDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI.
Mubin TarannumDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Khanhlinh DinhDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Yasmin AbdulhamidDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Roman ShapiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Rebecca PorterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Robert SoifferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jerome RitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-5526-4669
John KorethDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Yun WeiDepartment of Chemistry and Chemical Engineering, Northeastern University, Boston, MA.
Peiru ChenDepartment of Chemistry and Chemical Engineering, Northeastern University, Boston, MA.
Ke ZhangDepartment of Bioengineering, Northeastern University, Boston, MA.
Valeria Márquez-PellegrinDepartment of Bioengineering, Northeastern University, Boston, MA.
Shanna BonannoDepartment of Bioengineering, Northeastern University, Boston, MA.
Neel JoshiDepartment of Chemistry and Chemical Engineering, Northeastern University, Boston, MA.
Ming GuanDepartment of Bioengineering, Northeastern University, Boston, MA.
Mengdi YangDepartment of Bioengineering, Northeastern University, Boston, MA.
Deng LiDepartment of Bioengineering, Northeastern University, Boston, MA.
Chiara BelliniDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jianzhu ChenKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
David BarbieDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jiahe LiDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI.
Rizwan RomeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9077-4736
Dana-Farber Cancer Institute · USNortheastern University · USHarvard University · USUniversity of Michigan · USMassachusetts General Hospital · USMassachusetts Institute of Technology · US

Funding

Single Cell and ImmunogenomicsP01CA229092 · NCI · DANA-FARBER CANCER INST · PI SOIFFER, ROBERT JON · 2019 to 2023
$13.8M
Enzymatic and genetic strategies for targeting disease-associated microbial metabolitesDP2GM154019 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jiahe Li · 2023 to 2026
$2.3M
NCI NIH HHS P01 CA229092NIGMS NIH HHS DP2 GM154019
6 · The paper itself

Abstract

Given the safety, tumor tropism, and ease of genetic manipulation in non-pathogenic

Identifiers

PMID38562821
PMCPMC10984091
OpenAlexW4393078212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.